Pelthos Therapeutics Inc. has announced a significant merger agreement with Castle Creek Biosciences, which is expected to enhance its position in the biological products industry. The merger, which involves two transactions, will see Castle Creek become a wholly owned subsidiary of Pelthos, allowing the company to expand its operational capabilities and market reach. This move is seen as a strategic effort to strengthen Pelthos’ portfolio and drive future growth.

On October 30, 2026, Pelthos Therapeutics, a Nevada corporation, entered into an agreement with Castle Creek Biosciences, a Delaware corporation. The merger will be executed in two phases: first, a merger of Pelthos’ wholly owned subsidiary with Castle Creek, followed by a second merger with another subsidiary, thereby consolidating operations under Pelthos. This dual-merger approach is designed to qualify as a tax-free reorganization under federal tax laws.

Pelthos Therapeutics operates in the biological products sector, focusing on innovative therapies and treatments. The company trades on the NYSE under the ticker symbol PTHS. The merger with Castle Creek is expected to enhance Pelthos' market share and product offerings, particularly in the development of new therapies.

The SEC filing details that at the effective time of the merger, Castle Creek stockholders will receive a significant number of shares of Pelthos common stock, along with potential milestone payments based on the performance of new products developed post-merger. Specifically, the agreement outlines that Castle Creek stockholders will be entitled to 5,200,000 shares of Pelthos common stock, with additional contingent shares based on future milestones related to product sales and FDA approvals.

In addition to the merger agreement, Pelthos has also entered into a securities purchase agreement with several investors, including Ligand Pharmaceuticals and Nomis Bay Ltd. This agreement involves the sale of Series B Convertible Preferred Stock and warrants to purchase Pelthos common stock, further solidifying the company’s financial foundation.

The merger and the associated financing are expected to impact various stakeholders, including current Pelthos shareholders, Castle Creek stockholders, and the broader market for biological products. The integration of Castle Creek’s assets and expertise is anticipated to create synergies that will enhance Pelthos' research and development capabilities.

Looking ahead, the completion of the merger is contingent upon several conditions, including stockholder approvals and regulatory clearances. The filing indicates that Pelthos plans to file a registration statement with the SEC to facilitate the issuance of new shares related to the merger. The company is also required to comply with the Hart-Scott-Rodino Antitrust Improvements Act, ensuring that the merger does not violate any antitrust regulations.

As Pelthos moves forward with this significant merger, it aims to position itself as a leader in the biological products market, leveraging the strengths of Castle Creek to drive innovation and growth. The strategic combination of both companies is expected to yield substantial benefits in the coming years.